| Code | CSB-RA015318MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to the reference antibody described in US10513561B2, specifically targeting MYL9 (Myosin Light Chain 9). MYL9 is a regulatory light chain of non-muscle myosin II that plays a critical role in cytoskeletal organization, cell motility, and contractility through calcium-dependent and phosphorylation-mediated mechanisms. This protein is essential for various cellular processes including cell adhesion, migration, and cytokinesis. Dysregulation of MYL9 has been implicated in cardiovascular diseases, hypertension, cancer metastasis, and inflammatory conditions, making it an important target for understanding disease mechanisms and cellular dynamics.
The reference antibody patent US10513561B2 provides the framework for this biosimilar development, ensuring consistent binding specificity and performance characteristics. This antibody serves as a valuable research tool for investigating MYL9 expression patterns, localization studies, and its functional roles in smooth muscle contraction and non-muscle cell motility. It enables researchers to explore MYL9-mediated signaling pathways and its involvement in pathological conditions across multiple research disciplines.
There are currently no reviews for this product.